Endocrinology, Vol 125, 773-777, Copyright © 1989 by Endocrine Society

ARTICLES

Purified preparations of the amniotic fluid-derived insulin-like growth factor-binding protein contain multimeric forms that are biologically active

WH Busby, P Hossenlopp, M Binoux and DR Clemmons
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill 27599.

The insulin-like growth factors (IGFs) appear to be secreted into interstitial fluids by many cell types, along with specific, high affinity binding proteins (IGF-BPs). These proteins, therefore, have the potential to bind IGF-I and -II and modify their ability to interact with specific cell surface receptors In these studies we report the detection of high mol wt, multimeric forms of one form of IGF-BP that has been purified from human amniotic fluid. The multimeric forms, which are either not or barely detectable in native amniotic fluid, are the result of intermolecular disulfide bond formation and can be reduced to a monomeric form by exposure to dithiothreitol. After reduction, the multimers are reduced to either monomeric or dimeric forms, as detected by Western blotting. The multimers can be separated from monomeric and dimeric forms by gel filtration chromatography. The purified multimers were fully biologically active in potentiating the effect of IGF-I on porcine aortic smooth muscle cell DNA synthesis. The monomeric form was also bioactive. No significant differences in the affinity of the monomeric and multimeric forms for IGF-I or -II could be detected. In summary, multimeric forms of this form of IGF-BP are detected during purification. The formation of these multimers is through intermolecular disulfide bonds and does not disrupt IGF binding or potentiation of the cellular growth response to IGF-I. These findings indicate that these higher mol wt forms may be fully active in biological test systems.

This article has been cited by other articles:

				D. R. Clemmons Use of Mutagenesis to Probe IGF-Binding Protein Structure/Function Relationships Endocr. Rev., December 1, 2001; 22(6): 800 - 817. [Abstract] [Full Text] [PDF]

				M. Westwood, J. D. Aplin, I. A. Collinge, A. Gill, A. White, and J. M. Gibson alpha 2-Macroglobulin: a New Component in the Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-1 Axis J. Biol. Chem., November 2, 2001; 276(45): 41668 - 41674. [Abstract] [Full Text] [PDF]

				K. Sakai, A. J. D'Ercole, L. J. Murphy, and D. R. Clemmons Physiological Differences in Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Phosphorylation in IGFBP-1 Transgenic Mice Diabetes, January 1, 2001; 50(1): 32 - 38. [Abstract] [Full Text]

				S. M. Twigg, M. C. Kiefer, J. Zapf, and R. C. Baxter Insulin-like Growth Factor-binding Protein 5 Complexes with the Acid-labile Subunit. ROLE OF THE CARBOXYL-TERMINAL DOMAIN J. Biol. Chem., October 30, 1998; 273(44): 28791 - 28798. [Abstract] [Full Text] [PDF]

				B. C. Villafuerte, W. Zhao, A. C. Herington, R. Saffery, and L. S. Phillips Identification of an Insulin-responsive Element in the Rat Insulin-like Growth Factor-binding Protein-3 Gene J. Biol. Chem., February 21, 1997; 272(8): 5024 - 5030. [Abstract] [Full Text] [PDF]

				K. Sakai, W. H. Busby Jr., J. B. Clarke, and D. R. Clemmons Tissue Transglutaminase Facilitates the Polymerization of Insulin-like Growth Factor-binding Protein-1 (IGFBP-1) and Leads to Loss of IGFBP-1's Ability to Inhibit Insulin-like Growth Factor-I-stimulated Protein Synthesis J. Biol. Chem., March 16, 2001; 276(12): 8740 - 8745. [Abstract] [Full Text] [PDF]